Enhanced Nitric Oxide-Releasing Materials

描述(由申请人提供)： 该项目的目标是开发一类一氧化氮释放材料(NOM)，通过将一氧化氮(NO)供体化合物添加到聚合物中形成。在这一努力的第一阶段，增强的标准释放NO持续很长一段时间，其速率超过正常内皮的释放。第一阶段的NO供体配方将与商业上可用的生物聚合物相结合。产生的标准将用于治疗人造血管移植物，将在绵羊的长期植入实验中进行测试，以评估该材料在延长通畅率方面的效果。该项目的目标是专注于开发一种具有改善长期通畅性的人造血管移植物，作为Norm的商业应用。为实现这一目标而取得的NORAME技术进步预计将导致这项技术的其他应用。 如果成功，Norm技术有可能为人造血管移植物领域做出实质性贡献。仅为血液透析途径植入的移植物数量就是一个相当大且不断增长的市场。一年后，下肢搭桥和血液透析移植物的失败率约为40%。早期血栓形成是常见的，由于内膜增生导致的长期衰竭也是常见的。从NORMAL中释放的一氧化氮可能有助于防止短期和长期的故障模式。一项初步研究显示，短期内受益的结果令人振奋。

DESCRIPTION (provided by applicant): The goal of this project is to develop a family of nitric oxide-releasing materials (NORM), formed by adding nitric oxide (NO) donor compounds to polymers. The enhanced NORM developed in Phase I of this effort released NO for a prolonged period of time, at rates exceeding the release of the normal endothelium. The NO donor formulations from Phase I will be combined with commercially-available biopolymers. The resulting NORM will be used to treat prosthetic vascular grafts, which will be tested in long-term implantation experiments in sheep to evaluate the efficacy of the materials in prolonging patency. The goal of the project is to focus on developing a prosthetic vascular graft with improved long-term patency as a commercial application of NORM. The advances in NORM technology achieved in pursuit of this goal is expected to lead to other applications of this technology. If successful, NORM technology has the potential to contribute substantially to the field of prosthetic vascular grafts. The number of grafts implanted for hemodialysis access alone is a sizeable and growing market. Failure rates with prosthetic grafts are approximately 40% after one year for lower extremity bypass and hemodialysis grafts. Early thrombosis is common, as is long-term failure due to intimal hyperplasia. Nitric oxide released from NORM may potentially contribute to preventing short- and long-term failure modes. A pilot study showed promising results for short-term benefits.